NCT06000501View on ClinicalTrials.gov

Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

July 3, 2024

Study Completion Date

July 17, 2024

Conditions

Adult Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Serdexmethylphenidate/dexmethylphenidate

Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors

collaborator

Corium, Inc.

INDUSTRY

lead

NYU Langone Health

OTHER

NCT06000501 - Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening | Biotech Hunter | Biotech Hunter